← Evidence map

TrialPediatric dermatology

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Lawrence F Eichenfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

2 trials

NCT04804605phase 31,220 enrolled2021 NCT04845620phase 3652 enrolled2021

Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). | Socratic